Ivacaftor-Induced Proteomic Changes Suggest Monocyte Defects May Contribute to the Pathogenesis of Cystic Fibrosis.
作者信息
Hisert Katherine B, Schoenfelt Kelly Q, Cooke Gordon, Grogan Brenda, Launspach Jan L, Gallagher Charles G, Donnelly Seamas C, Welsh Michael J, Singh Pradeep K, McKone Edward F, Becker Lev
机构信息
1 University of Washington Seattle, Washington.
2 University of Chicago Chicago, Illinois.
出版信息
Am J Respir Cell Mol Biol. 2016 Apr;54(4):594-7. doi: 10.1165/rcmb.2015-0322LE.
Abstract
摘要
相似文献
1
Ivacaftor-Induced Proteomic Changes Suggest Monocyte Defects May Contribute to the Pathogenesis of Cystic Fibrosis.
Am J Respir Cell Mol Biol. 2016 Apr;54(4):594-7. doi: 10.1165/rcmb.2015-0322LE.
2
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
Sci Rep. 2018 Nov 20;8(1):17066. doi: 10.1038/s41598-018-35151-7.
3
Potentiation of the cystic fibrosis transmembrane conductance regulator Cl channel by ivacaftor is temperature independent.
Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L846-L857. doi: 10.1152/ajplung.00235.2018. Epub 2018 Aug 23.
4
Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75. doi: 10.1345/aph.1R076. Epub 2012 Jun 26.
5
CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Pediatr Pulmonol. 2017 Jul;52(7):900-908. doi: 10.1002/ppul.23712. Epub 2017 Apr 26.
6
The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Ann Am Thorac Soc. 2020 Feb;17(2):147-154. doi: 10.1513/AnnalsATS.201909-671CME.
7
The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
Am J Respir Cell Mol Biol. 2017 Jan;56(1):99-108. doi: 10.1165/rcmb.2016-0226OC.
8
An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
ACS Infect Dis. 2016 Jul 8;2(7):478-88. doi: 10.1021/acsinfecdis.6b00035. Epub 2016 May 17.
9
Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
Drugs. 2019 Dec;79(18):2001-2007. doi: 10.1007/s40265-019-01233-7.
10
Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
Ther Adv Respir Dis. 2015 Aug;9(4):198-200. doi: 10.1177/1753465815579364.
引用本文的文献
1
Recent developments in cystic fibrosis drug discovery: where are we today?
Expert Opin Drug Discov. 2025 May;20(5):659-682. doi: 10.1080/17460441.2025.2490250. Epub 2025 Apr 13.
2
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251323194. doi: 10.1177/17534666251323194. Epub 2025 Mar 31.
3
CFTR dictates monocyte adhesion by facilitating integrin clustering but not activation.
Proc Natl Acad Sci U S A. 2025 Jan 21;122(3):e2412717122. doi: 10.1073/pnas.2412717122. Epub 2025 Jan 15.
4
Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.
Genes (Basel). 2023 Oct 20;14(10):1966. doi: 10.3390/genes14101966.
5
Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages.
Sci Rep. 2023 Jul 25;13(1):11995. doi: 10.1038/s41598-023-38300-9.
6
Respiratory Infection and Inflammation in Cystic Fibrosis: A Dynamic Interplay among the Host, Microbes, and Environment for the Ages.
Int J Mol Sci. 2023 Feb 17;24(4):4052. doi: 10.3390/ijms24044052.
7
Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosis.
Cell Rep. 2022 Dec 13;41(11):111797. doi: 10.1016/j.celrep.2022.111797.
8
The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.
Clin Chest Med. 2022 Dec;43(4):647-665. doi: 10.1016/j.ccm.2022.06.007.
9
Impact of Modulators on the Impaired Function of Phagocytes in Cystic Fibrosis Lung Disease.
Int J Mol Sci. 2022 Oct 17;23(20):12421. doi: 10.3390/ijms232012421.
10
Emerging Concepts in Defective Macrophage Phagocytosis in Cystic Fibrosis.
Int J Mol Sci. 2022 Jul 13;23(14):7750. doi: 10.3390/ijms23147750.
本文引用的文献
1
Origins of cystic fibrosis lung disease.
N Engl J Med. 2015 Jan 22;372(4):351-62. doi: 10.1056/NEJMra1300109.
2
Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages.
Cell Metab. 2014 Oct 7;20(4):614-25. doi: 10.1016/j.cmet.2014.08.010. Epub 2014 Sep 18.
3
Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation.
Thorax. 2013 Jun;68(6):532-9. doi: 10.1136/thoraxjnl-2012-202538. Epub 2013 Feb 9.
4
Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection.
J Leukoc Biol. 2012 Nov;92(5):1111-22. doi: 10.1189/jlb.0412188. Epub 2012 Aug 2.
5
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.
6
Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis.
PLoS One. 2011;6(7):e22212. doi: 10.1371/journal.pone.0022212. Epub 2011 Jul 21.
7
Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa.
PLoS One. 2011;6(5):e19970. doi: 10.1371/journal.pone.0019970. Epub 2011 May 18.
8
Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis.
J Immunol. 2011 Jun 15;186(12):6990-8. doi: 10.4049/jimmunol.1100396. Epub 2011 May 18.
9
Endotoxin tolerance: new mechanisms, molecules and clinical significance.
Trends Immunol. 2009 Oct;30(10):475-87. doi: 10.1016/j.it.2009.07.009. Epub 2009 Sep 24.
10
IFN-gamma and STAT1 arrest monocyte migration and modulate RAC/CDC42 pathways.
J Immunol. 2008 Jun 15;180(12):8057-65. doi: 10.4049/jimmunol.180.12.8057.
Zotero 插件